DNB Markets - Isofol Medical: Update on clinical development
Isofol Medical yesterday gave an update on several of its clinical programmes. The AGENT study has randomised 200+ patients and is rapidly approaching interim analysis in Q4 2020e. The company also reported the phase I/IIa study ISC-CC-005 had been concluded and a gene expression analysis method had been validated. We reiterate our SEK18–49 fair value.AGENT study progressing to plan; interim analysis rapidly approaching. The ongoing phase III AGENT is progressing according to plan and has randomised 200+ of the planned 440 patients. The trial is rapidly approaching the next milestone of 330